A fluoroquinolone antibiotic
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Gemifloxacin (mesylate)

Item No. 21047

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, monomethanesulfonate
CAS Number
210353-53-0
Synonyms
  • LB 20304a
  • SB 265805S
Molecular Formula
C18H20FN5O4 • CH3SO3H
Formula Weight
485.5
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlDMSO: 15 mg/mlPBS (pH 7.2): 1 mg/ml
λmax
269, 341 nm
SMILES
OC(C1=CN(C2CC2)C3=C(C=C(F)C(N(C/4)CC(CN)C4=N\OC)=N3)C1=O)=O.OS(=O)(C)=O
InChi Code
InChI=1S/C18H20FN5O4.CH4O3S/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17;1-5(2,3)4/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27);1H3,(H,2,3,4)/b22-14+;
InChi Key
JIYMVSQRGZEYAX-CWUUNJJBSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $41

    Add

    10 mg

    $69

    Add

    25 mg

    $131

    Add

    50 mg

    $169

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Gemifloxacin is a fluoroquinolone antibiotic that is effective against C. pneumoniae and M. tuberculosis (MIC50s = 0.25 and 8 µg/ml, respectively).1,2 Quinolones, including gemifloxacin, inhibit bacterial DNA gyrase and other topoisomerases.3,4 Formulations containing gemifloxacin are useful against respiratory tract infections, particularly community-acquired pneumonia and tuberculosis.1,5,6

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Hammerschlag, M.R., Roblin, P.M., and Bébéar, C.M. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens. J. Antimicrob. Chemother. 48(Topic T1), 25-31 (2001).

    2. Ruiz-Serrano, M.J., Alcalá, L., Martínez, L., et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob. Agents Chemother. 44(9), 2567-2568 (2000).

    3. Collin, F., Karkare, S., and Maxwell, A. Exploiting bacterial DNA gyrase as a drug target: Current state and perspectives. Appl. Microbiol. Biotechnol. 92(3), 479-497 (2011).

    4. Weigel, L.M., Anderson, G.J., and Tenover, F.C. DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis. Antimicrob. Agents Chemother. 46(8), 2582-2587 (2002).

    5. Grossman, R.F., Hsueh, P.-R., Gillespie, S.H., et al. Community-acquired pneumonia and tuberculosis: Differential diagnosis and the use of fluoroquinolones. Int. J. Infect. Dis. 18, 14-21 (2014).

    6. Pranger, A.D., Alffenaar, J.W.C., and Aarnoutse, R.E. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: A pharmacokinetic and pharmacodynamic approach. Curr. Pharm. Des. 17(27), 29002-29930 (2011).